Long-term Safety of Ranibizumab in Neovascular Age-related Macular Degeneration
We read with interest the study from Silva et al on the long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration (nAMD). It described visual outcomes, drug tolerability, and safety of ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland, and Genentech, Inc, South San Francisco, CA) over a 24-month follow-up in selected patients with nAMD previously treated for 1 year in other studies on ranibizumab. The authors concluded that ranibizumab administered as per a visual acuity-guided flexible dosing regimen was well tolerated, and observed that on average, mean best-corrected visual (Read more...)